About Corpora.ai

A new foundation for frontier science.

Corpora.ai is a UK-based technology company, co-founded by Mel Morris CBE and Joe Jaroch, building the data architecture and research capabilities that frontier science, frontier ventures, and frontier institutions actually require.

Talk to us
Why we exist

Research is inherently constrained by a fundamental limitation: the gap between knowledge that exists and what you can find, connect, and act on within the time and budget available.

  1. Unseen

    One unseen connection

    and a breakthrough is missed.

  2. Overlooked

    One overlooked data point

    and a strategy misfires.

  3. Late

    One trend spotted too late

    and something possible is judged impossible.

Other tools leave mountains of relevant content unsearched and call it coverage.

The answer

Frontier research demands a different standard. Corpora.ai replaces the foundation. The result is research that is higher quality, much faster, and dramatically more efficient - and a set of programs that turn that capability into measurable outcomes.

Co-founders

Built by builders.

Mel Morris CBE

Mel Morris CBE

Co-founder & Executive Chair

One of the UK's most successful entrepreneurs, with eight successful business exits valued in total at more than $7Bn. Within Corpora.ai, Mel provides direct entrepreneurial mentorship, pre-seed capital to selected ventures through the Crucible program, and the onward referral network into a curated set of partner venture capital firms for follow-on funding.

Joe Jaroch

Joe Jaroch

Co-founder & Technical Architect

Joe has built pioneering software in cybersecurity and applied AI/ML, generating billions of dollars in revenue across millions of users. He is the technical architect behind ColossioDB, the unified foundation on which the rest of the platform sits, enabling millisecond queries against petabytes of data.

Professors in Residence

Senior practitioners whose direct domain experience anchors the programs.

Where Catalyst provides evidence at depth, the Professors provide judgement at the level a venture's next funder, a research program's next reviewer, or a corporate sponsor's technical due diligence team expects to see.

  • Professor Paul StewartEngineering, Advanced Management & Control Systems

    Vast experience in engineering and advanced management and control systems across aerospace and nuclear. For ventures whose technical claim rests on control systems, complex engineering integration, or safety-critical applications, his judgement on design realism, certification path, and operational risk is the kind of input that institutional investors and corporate sponsors typically only access through expensive specialist consultancies.

  • Dr Alexander ReipMaterials Science & Chemistry

    A highly respected materials scientist and Master of Chemistry whose direct experience covers materials development, characterisation, and the translation of laboratory chemistry into commercial process. For programs in advanced materials, novel chemistry, energy materials, and adjacent fields, his judgement on technical feasibility, scale-up risk, and IP defensibility is anchored in decades of practical work.

  • Professor Andy PardoeArtificial Intelligence

    One of the most publicly recognised AI voices in the UK and a well-publicised AI professional with deep experience across applied AI, AI strategy, and the public discourse around the technology. For frontier AI work, AI-enabled deep-tech, and AI in regulated or safety-critical contexts, his judgement is genuinely difficult to source elsewhere at the same level.

  • Dr Aqib BhattiClinical Medicine & Healthcare Systems

    Considerable experience as a practising General Physician and Medical Director for one of the largest service providers to the NHS. For health-tech, medical-device, digital-health, and clinical-software programs, his judgement covers both clinical realism and the operational reality of NHS-scale healthcare delivery - including procurement, integration with existing care pathways, regulatory expectations, and the practical economics of clinical adoption.

  • Mel Morris CBEEntrepreneurship, Capital & the Investor Network

    Eight successful business exits valued in total at more than $7Bn. Within Corpora.ai's programs - and in addition to his role as co-founder of the company - Mel provides direct entrepreneurial mentorship, pre-seed capital to selected ventures through Crucible, and the onward referral network into a curated set of partner venture capital firms for follow-on funding.

The compounding effect

The compounding across them is more significant than the sum.

Each constituency benefits individually.

  • Higher fee income, larger corporate sponsorships, more grants won, faster IP-to-licensing pathway, step change in strategic visibility.

  • Frontier-grade research capacity, IP framed up front, defensible novelty position, and the ability to start practical work immediately.

  • A credible pathway from frontier idea to investor-ready venture, without becoming generalist business operators before the science attracts capital.

  • Curated, pre-validated deal flow; shorter and more defensible diligence; higher conviction; portfolio value-creation at portfolio scale.

Talk to us

Engage from the front of the flywheel - not the back.